Cargando…
Effects of losartan vs candesartan in reducing cardiovascular events in the primary treatment of hypertension
Although angiotensin receptor blockers have different receptor binding properties no comparative studies with cardiovascular disease (CVD) end points have been performed within this class of drugs. The aim of this study was to test the hypothesis that there are blood pressure independent CVD-risk di...
Autores principales: | Kjeldsen, S E, Stålhammar, J, Hasvold, P, Bodegard, J, Olsson, U, Russell, D |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2834374/ https://www.ncbi.nlm.nih.gov/pubmed/19890371 http://dx.doi.org/10.1038/jhh.2009.77 |
Ejemplares similares
-
Health-care costs of losartan and candesartan in the primary treatment of hypertension
por: Henriksson, M, et al.
Publicado: (2011) -
Cost-effectiveness of candesartan versus losartan in the primary preventive treatment of hypertension
por: Granström, Ola, et al.
Publicado: (2012) -
Diabetes and CVD risk during angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker treatment in hypertension: a study of 15 990 patients
por: Hasvold, L P, et al.
Publicado: (2014) -
Association Between Paradoxical HDL Cholesterol Decrease and Risk of Major Adverse Cardiovascular Events in Patients Initiated on Statin Treatment in a Primary Care Setting
por: Hasvold, Pål, et al.
Publicado: (2015) -
Candesartan, rather than losartan, improves motor dysfunction in thioacetamide-induced chronic liver failure in rats
por: Murad, H.A., et al.
Publicado: (2017)